Contingency Management for Meth in South Africa Methamphetamine Abuse in South Africa

Not Applicable

Completed

• Conditions: Methamphetamine Abuse
• Interventions: Behavioral: Contingency Management

• Registration Number: NCT02907853
• Lead Sponsor: University of California, Los Angeles

Brief Summary

This study will link findings from neuroscience with clinical outcomes using contingency management (CM) to identify changes in brain structure and function that emerge during purely behavioral therapy for methamphetamine (MA) use.

Detailed Description

This study will correlate MA-abstinence outcomes from an 8-week program of voucher-based incentives using an escalating schedule for 30 treatment-seeking, MA-dependent individuals with scores on tasks of working memory and assessments of neuropsychological and demographic status. At the beginning and end of the CM program, participants will participate in MRI scans while performing a working memory task and will complete a battery of select neurocognitive and psychological assays to address two specific aims: (1) to determine whether changes in neural function within frontostriatal circuitry from baseline to end of the 8-week CM program are associated with parallel changes in measures of cognitive control and impulsivity and with MA abstinence outcomes and (2) to determine whether structural changes in frontostriatal circuitry over the 8-week CM intervention correspond with neurocognitive, psychological and MA abstinence measures.

Study Timeline

• Study Start: 2015-09-01
• Study First Submitted: 2016-09-13
• Study First Submitted QC: 2016-09-15
• Study First Posted: 2016-09-20
• Primary Completion: 2018-02-15
• Study Completion: 2018-02-15
• Status Verified: 2019-05
• Last Update Submitted: 2019-05-08
• Last Update Posted: 2019-05-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

• provide voluntary informed consent
• meet DSM-5 criteria for MA or amphetamine use disorder
• provide at least one urine sample positive for MA/amphetamine metabolites during screening (i.e. prior to the commencement of the study).
• aged 18-45
• right-handed
• English-speaking

Read More

Exclusion Criteria

• currently receiving treatment for stimulant addiction or needing more intensive treatment than outpatient care
• meet DSM-5 criteria for substance use disorder other than nicotine
• unable to attend 4+ visits during the 2-week screening period or to complete measures
• Physical or mental illness that would require intervention that would alter imaging or that would interfere with safe study participation
• pregnant, claustrophobic, or have metal prostheses, cardiac pacemakers, or metal clips that are incompatible with the scanner
• HIV positive status
• unable to comprehend written or spoken English
• currently taking psychiatric medication

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Contingency Management	Contingency Management	In exchange for consecutive urine samples documenting methamphetamine abstinence, participants receive increasingly valuable reinforcers.

Primary Outcome Measures

Name	Time	Method
Responses to Contingency Management	8 weeks	urine samples documenting methamphetamine abstinence
fMRI Measures	Change b/w baseline and 8 Weeks	measures of resting state connectivity

Secondary Outcome Measures

Name	Time	Method
Continuous Performance Task	Change b/w baseline and 8 Weeks	test of sustained attention
Stroop	Change b/w baseline and 8 Weeks	test of inhibitory control
Stop Signal Task	Change b/w baseline and 8 Weeks	measure of inhibitory control
Balloon Analog Risk Task	Change b/w baseline and 8 Weeks	measure of risk taking and decision making

Trial Locations

Locations (1)

Department of Psychiatry at Groote Schuur Hospital; 🇿🇦 Cape Town, South Africa